ОбзорГрафикНовостиTraderScreen

ING Knock-Out RO/  DE000NG8RW34  /

Frankfurt Zertifikate
13.11.2024  16:38:02 Изменение-0.060 Бид17:14:27 Предложение17:14:27 Базовый актив Цена исполнения Дата истечения Тип опциона
14.160EUR -0.42% -
Величина цены спроса: -		 -
Величина цены предложения: -		 ROCHE I 151.506 CHF 31.12.2078 Call
TeleTrader 23.10 Roche's Q3 sales up 6% to 15.1B Swiss francs
Newsfile Corp 11.10 JRR Marketing Announces Launch of New Book "5 Ways to Get Strangers to Want to Buy Your Stuff" to He...
Newsfile Corp 02.10 First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire 26.08 First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire 19.08 LIXTE Biotechnology Provides Update On Recent Activities and Developments
TeleTrader 25.07 Europe lower premarket as earnings pour in
TeleTrader 25.07 Roche's H1 sales at 29.85 billion Swiss francs
GlobeNewswire 27.06 Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
GlobeNewswire 18.06 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 14.06 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire 11.06 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
TeleTrader 27.05 Roche shuffles its executive committee
TeleTrader 16.05 Roche notes progress in obesity drug trial
GlobeNewswire 09.05 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 07.05 Enable Injections Expands Strategic Partnership with Roche
TeleTrader 24.04 Roche's logs 14.4 billion Swiss francs in Q1 sales
GlobeNewswire 03.04 UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire 02.04 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 14.03 Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire 26.02 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire 21.02 REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
TeleTrader 01.02 Roche's 2023 sales increase 1% to 58.7B Swiss francs
GlobeNewswire 29.01 Carmot Therapeutics Announces Completion of Acquisition by Roche
GlobeNewswire 03.01 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire 03.01 Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...